Stock Price of Bristol-Myers Squibb Company (BMY) Increases 1.71%

Bristol-Myers Squibb Company s in-depth stock price analysis indicates that the stock price has dropped -9% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -12.12% . Looking at the past 52 week period, the stock price is down -14.2% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Bristol-Myers Squibb Company has a negative value of -8.52 compared to overall market performance. Stocks of Bristol-Myers Squibb Company (NYSE:BMY) rallied by 1.71% during the past week but lost 8.13% on a 4-week basis. The company has outperformed the S&P 500 by 0.89% in the past week but underperformed the index by 9.77% in the last 4 weeks.

Bristol-Myers Squibb Company (NYSE:BMY) : On Friday heightened volatility was witnessed in Bristol-Myers Squibb Company (NYSE:BMY) which led to swings in the share price. The stock opened for trading at $51.61 and hit $51.97 on the upside , eventually ending the session at $51.65, with a gain of 0.27% or 0.14 points. The heightened volatility saw the trading volume jump to 5,845,618 shares. The 52-week high of the share price is $77.12 and the company has a market cap of $86,319 million. The 52-week low of the share price is at $46.01 .

Bristol-Myers Squibb Co Last issued its quarterly earnings results on Jan 26, 2017. The company reported $0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.66. The company had revenue of $5243.00 million for the quarter, compared to analysts expectations of $5133.31 million. The companys revenue was up 22.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Bristol-Myers Squibb Co was Upgraded by Jefferies to Buy on Dec 19, 2016.

Company has reported several Insider transactions to the SEC, on Sep 9, 2016, Lamberto Andreotti (director) sold 21,600 shares at 56.87 per share price.On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at 72.69 per share price.On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at 70.79 per share price.

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.


Share this post

Leave a Reply